...from Vyvanse lisdexamfetamine, an ADHD drug that is expected to face generic competition in 2022-23. Mydayis...
...June to treat ADHD, had 2017 sales of $21.6 million. The anonymous Shire investor said Mydayis...

...well as adrenergic receptor alpha 2A (ADRA2A) agonist Intuniv, for ADHD. The company also launched Mydayis...

...well as adrenergic receptor alpha 2A (ADRA2A) agonist Intuniv, for ADHD. The company also launched Mydayis...

...for ADHD. The company plans to launch Mydayis for the indication in 3Q17. FDA approved Mydayis...

...for ADHD. The company plans to launch Mydayis for the indication in 3Q17. FDA approved Mydayis...

...inadequately to one or more disease-modifying antirheumatic drugs (DMARDs) Shire plc (LSE:SHP; NASDAQ:SHPG) FDA approves Mydayis...

...FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients ages 13...
...LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: Mydayis mixed amphetamine salts (MAS) (SHP465) (formerly SPD465) Business: Neurology Alicia Parker Mydayis SHP465 triple-bead MAS Shire...

...FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients aged 13...
...will set Mydayis' price "in the coming week." The company first submitted an NDA for Mydayis...
...Shire gained 89.50p to 4,460p in London. Its shares rose $3.49 to $170.75 on NASDAQ. Alicia Parker triple-bead MAS Shire...

...Ltd. (Tokyo:4536) Opsiria sirolimus Non-infectious uveitis Submit NDA Early 2017 Shire plc (LSE:SHP; NASDAQ:SHPG) Triple-bead MAS (SHP465...

...FDA accepted for review a resubmitted NDA for SHP465 from Shire to treat ADHD. Its PDUFA...
...Shire first submitted the NDA in 2006 to treat adult ADHD. Shire hopes to launch SHP465...
...2016 ). Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: SHP465 (triple-bead MAS) (formerly SPD465) Business: Neurology Chris Lieu SHP465 triple-bead MAS Shire...